Genowis Secures RMB 60 Million Series B Financing Led by Summit Healthcare Capital to Advance Next-Generation Pathological Diagnosis
Recently,VCBeat has learned that precision medicine big data company Genome Wisdom Inc. has completed a RMB 60 millionBround of financing, led by Huagai Capital, WutongTreeCo-invested with the Qingkong Jinxin Blue Microbiology Fund; Legend Capital was the lead investor in the previous round.Capital, RestorationInvestmentBoth the company and its executive team increased their investments in this round.。
Dr. Ling Shaoping, CEO of Genome Wisdom Inc., stated that the company is committed to driving innovation in Next-Gen Pathological Diagnosis (NGPD) and building a new intelligent, precision oncology diagnostic big data platform for healthcare institutions.Intelligent Precision Cancer Diagnosis：iPCD), this round of financing will enable Genome Wisdom Inc. to accelerate the clinical application and implementation of its iPCD platform.
As a precision medicine big data company mastering multimodal AI technologies, Genome Wisdom Inc. will apply its proprietary AI algorithm system to address three major pain points in the innovation of Next-Generation Pathological Diagnosis (NGPD): structured pathological information, quantitative pathological imaging, and intelligent bioinformatics analysis. Its core product, iPCD, not only enables healthcare institutions to conduct NGS data analysis and deliver real-time reports more efficiently and accurately, but more importantly, integrates pathological information to provide clinically actionable, big data-driven integrated diagnostic decision support.
Since its inception in 2016, Genome Wisdom Inc. has completed three rounds of financing, with a total amount exceeding RMB 100 million. The angel round and Series A were led by ZhenFund and Legend Capital, respectively. The current round was led by Huagai Capital, a top-tier domestic private equity fund specializing in healthcare. This not only demonstrates the recognition by professional healthcare investors of Genome Wisdom’s strategic direction amid the capital winter, but also underscores the company’s determination to drive innovation in the Next-Generation Pathological Diagnosis (NGPD) system for oncology.。
In an interview, Meng Nan, Executive General Manager of the Healthcare Fund at Huagai Capital, stated, “We are optimistic about the application of big data and artificial intelligence in the healthcare sector. The team at Genome Wisdom Inc. is focused on establishing a next-generation tumor pathology diagnosis system. Its flagship core product, iPCD, addresses key pain points in precision diagnostics. The team not only possesses a profound understanding of the healthcare industry but also masters cutting-edge AI and big data technologies. Its products have gained consistent recognition from clinicians and customers across the upstream and downstream industry chain. We believe that Genome Wisdom Inc. will drive the development of precision medicine and lead the transformation of oncology diagnosis and treatment models in the era of artificial intelligence.”
When discussing the company’s advantages, Dr. Ling Shaoping, CEO of Genome Wisdom Inc., believes they can be summarized in four words:Focus, Team, Technique, and Platform—he refers to this as Genome Wisdom’s “FTTP” logic.。
First is Focus. Genome Wisdom Inc. stands at the multidisciplinary intersection of precision medicine omics technology applications, big data analytics in healthcare, and artificial intelligence.。
Initially, the company had numerous potential entry points. Its primary focus was established at inception on big data for precision oncology. This strategic choice was driven not only by the research backgrounds of the founding team but, more importantly, by the company’s ambitious vision to leverage AI and big data technologies to “connect data and empower smart cancer care.”
The second key focus lies in the company’s positioning to serve healthcare institutions engaged in diagnostic services, including hospital pathology departments and third-party diagnostic laboratories. By leveraging its proprietary multimodal AI technology, the company addresses practical pain points within customers’ specific application scenarios. Standardization of tumor pathology diagnosis is the first step toward achieving intelligent and precise diagnostics. Currently, the company is collaborating with pathology experts across China to establish standardized pathological diagnostic protocols for multiple cancer types, with plans to complete standardization for at least ten cancers in the near future.
Second is the excellent team (Team). In the field of precision medicine, the core executive team of Genome Wisdom Inc. is a star-studded group with top-tier industry strength and strong complementarity.。
CEO Ling Shaoping previously served as the Head of Bioinformatics Technology at the Beijing Institute of Genomics, Chinese Academy of Sciences. With over a decade of research experience in tumor genomics, bioinformatics, and artificial intelligence algorithms, his expertise spans high-performance computing architectures, AI algorithm design and implementation, and their applications in tumor genomic analysis.
He not only led his team to win the first gold medal for China in the International Gold Standard Competition for Tumor Genome Analysis, but also published in Nature Genetics,He has published multiple articles on cancer genomics research in top-tier journals such as PNAS, and was recently named “China’s 40 Under 40 Business Elites of 2019”。
The company’s CTO is Xu Zhao, former Senior Applications Specialist in Bioinformatics at Life Technologies in the United States (Dr. Xu Zhao Appointed as CTO of Genome Wisdom Inc.）, responsible for product engineering and cloud platform development.
Dr. Li Lixing, the company’s CIO, previously worked at Alibaba Youku and possesses a strong technical background in natural language processing, enabling Genome Wisdom Inc.’s NGS data analysis solution to seamlessly integrate with existing clinical information systems within hospitals.
The Company’s Chief Legal Officer is Mr. Wang Chunyang, a partner at Beijing Dacheng Law Offices, who safeguards the Company’s compliant operations.
Recently,Dr. Liu Kesheng, Former Head of NGS Technology at Life Technologies China, Joins Genome Wisdom Inc. as COODr. Liu previously conducted oncology research at the Whitehead Institute for Biomedical Research at MIT. Since returning to China, he has accumulated extensive expertise over more than a decade in next-generation sequencing (NGS) technology, market operations, and the clinical implementation of products. His joining will significantly accelerate the company’s clinical adoption and commercialization efforts.
Such a core team, possessing both cross-disciplinary technical expertise and market operation experience, is highly enviable in the field of precision medicine.
Genome Wisdom Inc. Core Team
Third is technological leadership (Technique). Genome Wisdom Inc. possesses a unique, independently developed multimodal AI technology system with proprietary intellectual property rights in bioinformatics analysis, natural language processing, and pathological image analysis.。
In the field of bioinformatics analysis, Genome Wisdom Inc. has achieved outstanding results in the “International Gold Standard Competition for Cancer Genome Analysis” and possesses an AI algorithm system for cancer genome analysis with independent intellectual property rights. In the area of natural language processing, the company owns a generalized AI model capable of processing various tumor pathology text reports and maintains the world’s largest Chinese pathology terminology database. In the realm of pathological imaging, the company has developed a series of AI technologies for quantitative analysis of the tumor immune microenvironment.
In the interview, Dr. Ling Shaoping stated, “These technologies not only help establish data management capabilities that integrate pathology and genomics, but more importantly, the platform provides decision support for integrated diagnostics based on big data analytics. We believe that as an increasing number of innovative oncology drugs enter clinical trials, more hospitals will begin to adopt these technologies and Genome Wisdom’s iPCD big data platform.”
Ling Shaoping emphasized: “Instrument and reagent manufacturers currently prioritize enabling hospitals to genuinely launch testing services. However, implementing next-generation sequencing (NGS) within hospitals demands high standards for data analysis speed, accuracy, and interpretation. Against this industrial backdrop, our technology outperforms existing open-source algorithms by 15 to 20 percentage points in handling production-grade large-panel data and whole-exome sequencing (WES). Furthermore, our data analysis throughput is 30 to 80 times faster than that of open-source algorithms, thereby meeting the timeliness and accuracy requirements of clinical applications.”
Launch of “Smart Gene Cloud 2.0”Since its launch, the product has gained widespread recognition from instrument and reagent kit manufacturers, IVD companies, and healthcare institutions, positioning the company as a leader in the field of tumor genomic analysis and clinical interpretation solutions. This product not only facilitates the successful deployment of vendors’ NGS instruments and high-quality reagents in hospitals but also addresses hospitals’ critical needs for data management, analysis, and clinical interpretation.
InRegarding the current industry ecosystem, Dr. Ling stated, to achieve precision diagnosis and treatment of tumors, the challenge faced by many upstream equipment and reagent manufacturers is how to integrate next-generation sequencing data analysis service capabilities into the current hospital diagnosis and treatment system.
The key bottlenecks in addressing this challenge lie in the accuracy of data analysis and clinical interpretation, the comprehensive integration of traditional diagnostic information, and the timeliness of report issuance. The iPCD platform being developed by Genome Wisdom Inc. not only incorporates the precise analysis and clinical interpretation capabilities of its previous Intelligent Gene Cloud NGS system, but also integrates historical pathological data to assist pathologists in making more accurate diagnoses, thereby providing clinicians with a more integrated report on diagnostic and therapeutic recommendations.
It is precisely due to Genome Wisdom’s deep expertise in the fields of bioinformatics and AI technology that leading gene sequencing equipmentManufacturerilluminaandMGI Tech, have all chosen Genome Wisdom Inc. as their partner for big data solutions. Recently, the achievements made by Genome Wisdom Inc. in deep strategic cooperation with upstream reagent manufacturers, customer contract signings, and hospital collaborations also reflect the industry-wide recognition and trust in the company’s products.
Fourth is the Platform effect. The company leveraged its own technologies and products to build China’s first big data platform for precision medicine—Cancer Moonshot. The platform was launched in collaboration with the Anti-Cancer Association“Multi-Center Research Project on Big Data of Tumor Pathology in China”, linking hundreds of thousands of clinical pathology records for oncology from over 100 Grade A tertiary hospitals. The platform is assisting professional associations in the field to establish next-generation pathological diagnostic standards. More importantly, it also incorporates multi-omics data, along with corresponding pathological and clinical information, from tens of thousands of cancer patients across 33 cancer types curated by the International Cancer Genome Consortium (ICGC), providing a reference basis for clinical practice and pharmaceutical research.
The platform’s database, intelligent analysis tools, and multi-center collaborative network mechanism provide a robust foundation for supporting clinical multi-center studies. Moving forward, Genome Wisdom Inc. will fully leverage its platform advantages to establish an in-hospital big data management and analysis platform integrating genomic and pathological information, and assist in developing data-sharing mechanisms among hospitals.
Looking to the future, artificial intelligence and big data technologies hold immense potential for application in the field of precision oncology. Leveraging its four core “FTTP” advantages, Genome Wisdom Inc. is leading the transformation of cancer diagnosis and treatment models in the AI era, working hand in hand with professional associations and corporate partners to advance the development of precision medicine!
Genome Wisdom Inc. is currently hiring. Interested candidates may scan the QR code below or search for “Genome Wisdom Inc.” on Liepin, Lagou, and BOSS Zhipin to submit their resumes.
